{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:52:20Z","timestamp":1773283940227,"version":"3.50.1"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.1001\/jamaophthalmol.2019.3947","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T19:52:14Z","timestamp":1570737134000},"page":"1389","source":"Crossref","is-referenced-by-count":23,"title":["Month 24 Outcomes After Treatment Initiation With Anti\u2013Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion"],"prefix":"10.1001","volume":"137","author":[{"given":"Ingrid U.","family":"Scott","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania"},{"name":"Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal L.","family":"Oden","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"VanVeldhuisen","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Ip","sequence":"additional","affiliation":[{"name":"Doheny Eye Institute, UCLA (University of California, Los Angeles)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Blodi","sequence":"additional","affiliation":[{"name":"Fundus Photograph Reading Center, University of Wisconsin\u2013Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Southern California Desert Retina, Palm Desert"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the SCORE2 Investigator Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"8","key":"eoi190070r1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/archopht.1993.01090080083022","article-title":"Baseline and early natural history report: the Central Vein Occlusion Study.","volume":"111","year":"1993","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"eoi190070r2","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0161-6420(95)30848-2","article-title":"A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report.","volume":"102","author":"Central Vein Occlusion Study Group","year":"1995","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi190070r3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/archopht.1997.01100150488006","article-title":"Natural history and clinical management of central retinal vein occlusion.","volume":"115","author":"Central Vein Occlusion Study Group","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"20","key":"eoi190070r4","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial.","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"issue":"20","key":"eoi190070r5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"eoi190070r6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ophtha.2016.09.038","article-title":"SCORE2 report 2: study design and baseline characteristics.","volume":"124","author":"Scott","year":"2017","journal-title":"Ophthalmology"},{"issue":"19","key":"eoi190070r7","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"5","key":"eoi190070r8","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"eoi190070r9","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi190070r10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi190070r11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"eoi190070r12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajo.2019.03.029","article-title":"Loss of peak vision in retinal vein occlusion patients treated for macular edema.","volume":"205","author":"Iftikhar","year":"2019","journal-title":"Am J Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2752549\/jamaophthalmology_scott_2019_oi_190070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T11:04:19Z","timestamp":1576148659000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2752549"}},"subtitle":["SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.3947","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}